|
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene | In Part 2 of 2, Dr. Haydar Frangoul discusses long-term safety and durability of gene editing in children with SCD and TDT, plus the infrastructure, specialized expertise, and referral pathways needed to expand access to treatment. | |
|
|
|
|
| Enabling MSC Harvest, Wash, And Concentration | Case Study | CARR Biosystems | A study demonstrates how a low-shear, closed-system centrifuge achieved over 90% MSC recovery and minimized viability loss, supporting scalable cell therapy manufacturing. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|